Becton, Dickinson and Company (BDX) to Issue Quarterly Dividend of $1.05 on September 30th

Becton, Dickinson and Company (NYSE:BDX) announced a quarterly dividend on Tuesday, July 28th. Investors of record on Wednesday, September 9th will be given a dividend of 1.05 per share by the medical instruments supplier on Wednesday, September 30th. This represents a c) annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Wednesday, September 9th.

Becton, Dickinson and Company has increased its dividend payment by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 53 years. Becton, Dickinson and Company has a payout ratio of 28.5% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Becton, Dickinson and Company to earn $13.24 per share next year, which means the company should continue to be able to cover its $4.20 annual dividend with an expected future payout ratio of 31.7%.

Becton, Dickinson and Company Price Performance

BDX opened at $184.78 on Monday. The firm has a market cap of $50.91 billion, a PE ratio of 55.66, a P/E/G ratio of 13.02 and a beta of 0.21. The stock has a 50-day moving average price of $170.05 and a 200-day moving average price of $160.58. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $193.07. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the business earned $3.68 EPS. Becton, Dickinson and Company’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.